I thank Dr Baird for his valuable comments. Indeed, it has been confirmed that CYP2B6 is the principal enzyme involved in the hydroxylation of bupropion (1) . Reports regarding the effect of methylphenidate (MPH) on the cytochrome P450 (CYP450) system are sparse, and to date, inhibition of CYP2B6 by MPH remains unproven. However, in vitro MPH inhibition of CYP2D1 and CYP2D has been demonstrated (2), and animal studies have shown inhibition of CYP1A, CYP2E1, and CYP3A by MPH (3). I agree with Dr Baird's suggestion that other isozymes of the CYP450 system may also affected by MPH; nevertheless, scientific evidence endorsing this hypothesis is not yet available.
Further studies are necessary to define the possible drug interactions of MPH with drugs metabolized by CYP450. Aggressive and hostile behaviours can be manifestations of schizophrenia, among other mental disorders (for example, mood disorders and dementia) (1) and contribute considerably to institutionalization (2) . In patients with chronic schizophrenia, clozapine treatment has resulted in a selective improvement in aggressive behaviour, beyond the global improvement shown on the Brief Psychiatric Rating Scale (BPRS) (3,4), although this improvement did not necessarily extend to the positive symptoms of psychosis (5). Risperidone treatment showed a greater selective effect on hostility in schizophrenia patients than did haloperidol or placebo (6), although there are some contradictory data from an open trial comparing risperidone and haloperidol (7). In clinical practice, risperidone has proven very useful in treating aggression and violence in patients with chronic refractory schizophrenia (8). In a case series, olanzapine had better, but not significantly different, tranquilizing properties after 3 days of treatment, compared with haloperidol (9). Quetiapine in high dosages (up to 900 mg daily) was used successfully in 2 treatment-resistant patients with schizophrenia and concomitant aggression (10,11). In the first instance, quetiapine was added to divalproex sodium (10), and in the second, it was coadministered with risperidone (11).
In this report, we describe the case of a patient with an unremitting acute psychotic episode whose hostility and aggressive symptoms improved soon after he was given combined quetiapine and risperidone.
Case Report
A 35-year-old, unmarried man was involuntarily admitted to our clinic. He showed auditory hallucinations, delusions of persecution and reference, aggressiveness, psychomotor agitation, and restricted affect. He appeared markedly dishevelled. His score on the Brief Psychiatric Rating Scale (BPRS), in which each item is rated 1 to 7, was 57; on tension, hostility, and agitation he had a score of 6 (severe). His psychiatric problems started about 3 years ago, when he stopped working and showed total social isolation, wandering, and untriggered and unpredictable verbal outbursts. He refused any psychiatric treatment and was diagnosed with schizophrenia, paranoid type, according to DSM-IV criteria.
He refused medication and was therefore given haloperidol 30 mg daily intramuscularly for 5 days. When he subsequently consented to take medication, risperidone was gradually added while the dosage of haloperidol was slowly tapered. After 20 days, his regimen consisted only of risperidone 12 mg daily. However, he did not show any sign of improvement, and any effort to stop restraint failed. As a result, after 1 week of risperidone monotherapy, quetiapine was added and titrated to 500 mg daily in 5-day intervals. When he was evaluated 1 week later, he showed marked improvement in symptoms, scoring 36 on the BPRS; on hostility and tension, he scored 2 (very mild), and on agitation, 3 (mild). After about 40 days of hospitalization the patient was released from restriction, and 2 weeks later, he was discharged from our clinic. His risperidone was decreased to 8 mg daily; no change was made in his daily quetiapine dosage. One month after discharge, his clinical state remains the same, with no The Canadian Journal of Psychiatry
